A Phase 2 interventional study of ETC-1002 and Placebo in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-04-04.
Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 18th largest by enrollment, is one of 2 that started in 2012, is one of 10 in phase 2, and was the 1st registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one is the 14th largest by enrollment, is one of 2 that started in 2012, is one of 9 in phase 2, and was the 1st registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the Low-Density Lipoprotein-Cholesterol (LDL-C) lowering efficacy and safety of ETC-1002 versus placebo in participants with hypercholesterolemia and a history of statin intolerance.
Key Inclusion Criteria:
Key Exclusion Criteria:
ETC-1002 treatment, once daily oral
Drug: ETC-1002
Placebo treatment, once daily oral
Drug: Placebo
Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day
Placebo once daily for 8 weeks
Percent Change From Baseline to Week 8 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. Least square (LS) mean percent change from Baseline to Week 8 was based on an analysis of covariance (ANCOVA) model with effects of treatment and Baseline value as a covariate. Missing LDL-C values at Week 8 were imputed using the last observation carried forward (LOCF) procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; 8 weeks
Percent Change From Baseline to Weeks 2, 4, 6, and 8 in Calculated LDL-C
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; Weeks 2, 4, 6, and 8
Percent Change From Baseline to Week 8 in High-Density Lipoprotein-Cholesterol (HDL-C)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; 8 weeks
Percent Change From Baseline to Week 8 in Non-HDL-C
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; 8 weeks
Percent Change From Baseline to Week 8 in Total Cholesterol
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; 8 weeks
Percent Change From Baseline to Week 8 in Triglycerides
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; 8 weeks
Percent Change From Baseline to Week 8 in Apolipoprotein B
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; 8 weeks
Percent Change From Baseline to Week 8 in Apolipoprotein AI
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; 8 weeks
Percent Change From Baseline to Week 8 in Lipoprotein (a)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data are based on the participant's last post-Baseline value. Only those participants having a valid assessment at Baseline and each subsequent time point were included in the summaries at that time point. Lipoprotein (a) results indicated as \<3 in the laboratory data were set to 3 for purposes of analysis. A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; 8 weeks
Percent Change From Baseline to Week 8 in High-Sensitivity C-Reactive Protein (hsCRP)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data were based on the participant's last post-Baseline value. Only those participants having a valid assessment at Baseline and each subsequent time point were included in the summaries at that time point. hsCRP results indicated as \<0.2 in the laboratory data were set to 0.2 for purposes of analysis. A negative percent change from Baseline reflects clinical improvement.
Time frame: Baseline; 8 weeks
Percent Change From Baseline to Week 8 in Free Fatty Acids (FFA)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data were based on the participant's last post-Baseline value.
Time frame: Baseline; 8 weeks
Number of Participants Achieving Their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) LDL-C Goal (<100 Milligrams Per Deciliter [mg/dL]) After 8 Weeks of Treatment
Participants were analyzed to evaluate the LDL-C target of \<100 mg/dL for high risk participants with cardiovascular diseases. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; up to 8 weeks
Number or Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as adverse events (AEs) that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.
Time frame: up to 8 weeks
Number of Participants With Muscle-Related TEAEs
TEAEs were defined as AEs that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.
Time frame: up to 8 weeks
| Milestone | ETC-1002 | Placebo |
|---|---|---|
| Started | 37 | 19 |
| Completed | 31 | 15 |
| Not completed | 6 | 4 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Per investigator/sponsor/regulatory body | 1 | 0 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. Least square (LS) mean percent change from Baseline to Week 8 was based on an analysis of covariance (ANCOVA) model with effects of treatment and Baseline value as a covariate. Missing LDL-C values at Week 8 were imputed using the last observation carried forward (LOCF) procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) | -32.0 ± 1.93 | -3.3 ± 2.69 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Week 2 | -19.5 ± 1.83 | -1.4 ± 2.52 |
| Week 4 | -31.0 ± 1.50 | -1.0 ± 2.12 |
| Week 6 | -32.6 ± 2.28 | -3.8 ± 3.28 |
| Week 8 | -32.6 ± 2.48 | -4.0 ± 3.51 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in High-Density Lipoprotein-Cholesterol (HDL-C) | -8.2 ± 2.46 | -2.4 ± 3.51 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Non-HDL-C | -25.4 ± 2.04 | -4.4 ± 2.88 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Total Cholesterol | -22.2 ± 1.64 | -3.7 ± 2.32 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Triglycerides | 11.2 ± 6.34 | -7.4 ± 8.98 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Apolipoprotein B | -19.7 ± 2.61 | -4.4 ± 3.77 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Apolipoprotein AI | -4.2 ± 2.04 | 0.1 ± 2.98 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data are based on the participant's last post-Baseline value. Only those participants having a valid assessment at Baseline and each subsequent time point were included in the summaries at that time point. Lipoprotein (a) results indicated as \<3 in the laboratory data were set to 3 for purposes of analysis. A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Lipoprotein (a) | 10.4 ± 5.78 | -1.2 ± 8.32 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data were based on the participant's last post-Baseline value. Only those participants having a valid assessment at Baseline and each subsequent time point were included in the summaries at that time point. hsCRP results indicated as \<0.2 in the laboratory data were set to 0.2 for purposes of analysis. A negative percent change from Baseline reflects clinical improvement.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in High-Sensitivity C-Reactive Protein (hsCRP) | -22.6 ± 11.77 | 1.1 ± 16.74 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data were based on the participant's last post-Baseline value.
| Percent Change | ETC-1002 | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Free Fatty Acids (FFA) | 14.3 ± 7.99 | 10.4 ± 11.31 |
Participants were analyzed to evaluate the LDL-C target of \<100 mg/dL for high risk participants with cardiovascular diseases. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Participants | ETC-1002 | Placebo |
|---|---|---|
| Week 8: Achieved LDL-C Goal | 21 | 0 |
| Week 8: Did Not Achieve LDL-C Goal | 13 | 17 |
TEAEs were defined as adverse events (AEs) that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.
| Participants | ETC-1002 | Placebo |
|---|---|---|
| Number or Participants With Treatment-emergent Adverse Events (TEAEs) | 26 | 15 |
TEAEs were defined as AEs that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.
| Participants | ETC-1002 | Placebo |
|---|---|---|
| Number of Participants With Muscle-Related TEAEs | 12 | 7 |
Collected over up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ETC-1002 | 0/37 (0%) | 1/37 (2.7%) | 19/37 (51.4%) |
| Placebo | 0/19 (0%) | 0/19 (0%) | 15/19 (78.9%) |
| Event | ETC-1002 | Placebo |
|---|---|---|
| Thyroid CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/37 | 0/19 |
| Event | ETC-1002 | Placebo |
|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 1/37 | 4/19 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 5/37 | 1/19 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/37 | 2/19 |
| Muscular WeaknessMusculoskeletal and connective tissue disorders | 1/37 | 2/19 |
| Musculoskeletal StiffnessMusculoskeletal and connective tissue disorders | 0/37 | 2/19 |
| NauseaGastrointestinal disorders | 3/37 | 0/19 |
| Urinary Tract InfectionInfections and infestations | 3/37 | 0/19 |
| FatigueGeneral disorders | 2/37 | 1/19 |
| NasopharyngitisInfections and infestations | 2/37 | 0/19 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 2/37 | 1/19 |
Baseline data are reported for members of the Safety Population, comprised of all randomized participants who received at least 1 dose of study medication.
| Age, Continuous(years) | ETC-1002 | Placebo | Total |
|---|---|---|---|
| Mean | 63.9 ± 5.42 | 60.4 ± 7.88 | 62.8 ± 6.51 |
| Sex: Female, Male(Participants) | ETC-1002 | Placebo | Total |
|---|---|---|---|
| Female | 17 | 11 | 28 |
| Male | 20 | 8 | 28 |
| Race (NIH/OMB)(Participants) | ETC-1002 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 35 | 19 | 54 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Calculated Low-density Lipoprotein Cholesterol (LDL-C)(milligrams per deciliter (mg/dL)) | ETC-1002 | Placebo | Total |
|---|---|---|---|
| Mean | 175.7 ± 36.52 | 184.8 ± 32.53 | 178.9 ± 35.16 |
Ran from Oct 2012 to primary completion in May 2013, 6 months.
Results were first posted in Apr 2022, 8 years 11 months after primary completion. A results delay was requested in Aug 2015.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 6 months is below that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid